Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma
about
Use of des-gamma-carboxyprothrombin in retrospective diagnosis of hidden intoxication of anticoagulantsAn update of biochemical markers of hepatocellular carcinomaPrediction of hepatocellular carcinoma biological behavior in patient selection for liver transplantationVitamin K and hepatocellular carcinoma: The basic and clinicBiomarkers: evaluation of screening for and early diagnosis of hepatocellular carcinoma in Japan and chinaTumor Markers for Hepatocellular Carcinoma: Simple and Significant Predictors of Outcome in Patients with HCCCirculating predictive and diagnostic biomarkers for hepatitis B virus-associated hepatocellular carcinomaGuide for diagnosis and treatment of hepatocellular carcinomaAsian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma.Diagnosis of hepatocellular carcinoma.Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients.AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver diseaseCurrent management of hepatocellular carcinoma.Present and future possibilities for early diagnosis of hepatocellular carcinomaScreening for hepatocellular carcinoma. Review and perspective.Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma.An autopsy case of hepatoid carcinoma of the ovary with PIVKA-II production: immunohistochemical study and literature review.Gla-rich protein is a potential new vitamin K target in cancer: evidences for a direct GRP-mineral interaction.Changes in highly sensitive alpha-fetoprotein for the prediction of the outcome in patients with hepatocellular carcinoma after hepatectomy.Abnormal prothrombin (DES-gamma-carboxy prothrombin) in hepatocellular carcinoma.Biomarkers for hepatocellular carcinoma: progression in early diagnosis, prognosis, and personalized therapyTreatment of fibrolamellar hepatoma with subtotal hepatectomy or transplantationGuidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults.Proteomic differences between hepatocellular carcinoma and nontumorous liver tissue investigated by a combined gel-based and label-free quantitative proteomics study.Diagnostic performance of alpha-fetoprotein, lens culinaris agglutinin-reactive alpha-fetoprotein, des-gamma carboxyprothrombin, and glypican-3 for the detection of hepatocellular carcinoma: a systematic review and meta-analysis protocol.K vitamins, PTP antagonism, and cell growth arrest.Protein induced by vitamin K absence or antagonist II-producing gastric cancer.Evaluation of individual and combined applications of serum biomarkers for diagnosis of hepatocellular carcinoma: a meta-analysis.Clinical utility of protein induced by vitamin K absence in patients with chronic hepatitis B virus infectionThe influence of alcoholic liver disease on serum PIVKA-II levels in patients without hepatocellular carcinoma.Diagnostic value of PIVKA-II and alpha-fetoprotein in hepatitis B virus-associated hepatocellular carcinomaIntestinal absorption of mixed micellar phylloquinone (vitamin K1) is unreliable in infants with conjugated hyperbilirubinaemia: implications for oral prophylaxis of vitamin K deficiency bleedingPrognostic roles of preoperative α-fetoprotein and des-γ-carboxy prothrombin in hepatocellular carcinoma patients.Usefulness of serum des-gamma-carboxy prothrombin in detection of hepatocellular carcinomaAptamer-based Sandwich Assay and its Clinical Outlooks for Detecting Lipocalin-2 in Hepatocellular Carcinoma (HCC).Utility of serum des-gamma-carboxyprothrombin in the diagnosis of hepatocellular carcinoma among Nigerians, a case-control studyGrowth inhibitory actions of prothrombin on normal hepatocytes: influence of matrix.Performance of Protein Induced by Vitamin K Absence or Antagonist-II (PIVKA-II) for Hepatocellular Carcinoma Screening in Chinese Population.Diagnostic Evaluation of Des-Gamma-Carboxy Prothrombin versus α-Fetoprotein for Hepatitis B Virus-Related Hepatocellular Carcinoma in China: A Large-Scale, Multicentre Study.Levels of plasma des-gamma-carboxy protein C and prothrombin in patients with liver diseases
P2860
Q24529089-FBDCF931-CE6F-4285-8333-A56CF2329FD8Q26752700-558F639F-809C-47FB-9FD7-4905E1C5DED1Q26772329-2732E2AC-2C79-4FFD-BC6C-10F5487556B4Q26783713-F66DB55E-783F-4A56-B60E-8CF43424CD32Q27003291-D1EE7EB9-4DD4-469E-A25A-992CF0407478Q27011253-5C6648EE-A224-4E91-B30A-8B1FC35A4C2BQ28080175-5B3FCE02-6BD2-47CF-84C1-C149AC41E018Q28084003-06B1E20C-06CE-4637-B354-04FBF1DD0C2AQ30479629-715AA14B-AB8F-448C-9152-39583BC88D8DQ30490554-35A7B20A-924E-40A8-8535-20B5B5EE2AB6Q31911652-8BEA937C-AB66-4932-B303-203430E124CCQ33353052-653E1C1F-BBEB-4260-BC46-FFD86BFA4101Q33582165-A2D5E53F-29EF-4AAF-9576-A2E1A5E0DBD5Q33612167-D809752E-E3AB-49AF-8B23-DBC76891F677Q33616024-A9948DB7-C875-479C-95AE-1A30EBE4DE6AQ33643368-BC2A013C-DAEF-4B53-B011-CA778915ECCBQ33651204-2CCA5723-CF3C-406A-BA49-72188B71E275Q33737404-87C4D3E7-CF64-43C4-9FC4-D8B096387AD6Q33913585-D04E4CE6-6AAE-48C6-A4FB-847200E2EF88Q34187638-D66A7B71-E42E-4876-9AEC-FB2E8695D0F5Q34256150-1B0AEA34-76F5-40D0-85D0-24FC84B63A93Q34421431-6E07FBC9-A3D3-477A-A740-438D8905CA85Q34532749-D3E3DBE9-1F9D-426E-9751-50C8DB638DCDQ34609315-CB0AD9EA-17E4-489A-9107-A58DB20BECC6Q34759365-DF7DF4EA-6271-471E-993D-6096F32CDB9AQ34972770-7C384BEA-21F2-4B46-B892-C5DA914D4BF6Q34992363-96438F4D-7843-4518-B9EE-A10BAD98EF89Q35062428-706B1452-D7F0-41D9-843B-BD943DB40AE8Q35125611-A010D274-98DE-4BDB-9EDD-26DCD4B4C8A6Q35151800-20E151EF-698B-41F0-A1EA-1290B2CF7A91Q35270302-F65CCD59-26E8-4145-8147-629049A26E75Q35292947-7A3F4190-C636-4B44-8B37-C7F75E30E001Q35534064-A8F5EC72-6E48-432F-93F1-BC2D6662FF5DQ35621312-838FFCE5-AC05-4D41-A7F8-91E310BFD206Q35678916-5B47E69B-54A7-418F-A624-B9590E38C6ABQ35764990-785D112D-0A3C-4D11-892D-659DADDD68C1Q35951527-1D9DFC53-9D29-48BC-9CDC-C4F2A6CF0C19Q35964785-96600702-FE10-4346-B97D-B5005A354E36Q35987232-04800E83-A5AB-456F-8241-B6C60A757DC6Q36076498-867215A4-A175-4EFF-B551-2291422232B7
P2860
Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma
description
1984 nî lūn-bûn
@nan
1984 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1984 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1984年の論文
@ja
1984年学术文章
@wuu
1984年学术文章
@zh-cn
1984年学术文章
@zh-hans
1984年学术文章
@zh-my
1984年学术文章
@zh-sg
1984年學術文章
@yue
name
Des-gamma-carboxy (abnormal) p ...... imary hepatocellular carcinoma
@ast
Des-gamma-carboxy (abnormal) p ...... imary hepatocellular carcinoma
@en
Des-gamma-carboxy (abnormal) p ...... imary hepatocellular carcinoma
@nl
type
label
Des-gamma-carboxy (abnormal) p ...... imary hepatocellular carcinoma
@ast
Des-gamma-carboxy (abnormal) p ...... imary hepatocellular carcinoma
@en
Des-gamma-carboxy (abnormal) p ...... imary hepatocellular carcinoma
@nl
prefLabel
Des-gamma-carboxy (abnormal) p ...... imary hepatocellular carcinoma
@ast
Des-gamma-carboxy (abnormal) p ...... imary hepatocellular carcinoma
@en
Des-gamma-carboxy (abnormal) p ...... imary hepatocellular carcinoma
@nl
P2093
P3181
P1476
Des-gamma-carboxy (abnormal) p ...... imary hepatocellular carcinoma
@en
P2093
H A Liebman
M S Coleman
R A Blanchard
P304
P3181
P356
10.1056/NEJM198405313102204
P407
P577
1984-05-31T00:00:00Z